NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

Clinical trial NCT04371224 · UNKNOWN

Trial details

NCT number: NCT04371224
Sponsor: Seoul National University Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Cancer

Start date: 2020-06-23
Primary completion: 2024-12-31
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.